import { type StudyTable, DataType } from "../types/study_table.d";

export const CerebelStudyTable: StudyTable = {
  study_id: "EGF111438",
  study_title:
    "CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer",
  table_name: "Table 1",
  table_title: "Patient Demographics and Disease and Treatment Characteristics",
  footnotes: [
    "Abbreviations: CISH, chromogenic in situ hybridization; ECOG, European Cooperative Oncology Group; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; MET, metastatic; SISH, silver in situ hybridization.",
  ],
  groups: [
    {
      name: "Lapatinib plus Capecitabine",
      n: 271,
      type: "intervention",
    },
    {
      name: "Trastuzumab plus Capecitabine",
      n: 269,
      type: "intervention",
    },
    {
      name: "Total",
      n: 540,
      type: "total",
    },
  ],
  characteristics: [
    {
      original_label: "Age, years",
      standardized_name: "Age",
      unit: "years",
      category: "Demographics",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "Age, years",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "Age, years",
        },
        {
          group_name: "Total",
          data_type: DataType.Header,
          raw_string: "Age, years",
        },
      ],
    },
    {
      original_label: "Median",
      standardized_name: "Age",
      unit: "years",
      category: "Demographics",
      is_sub_characteristic: true,
      sub_characteristic_of: "Age, years",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.NumericSingle,
          value: 53.0,
          raw_string: "53",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.NumericSingle,
          value: 56.0,
          raw_string: "56",
        },
        {
          group_name: "Total",
          data_type: DataType.NumericSingle,
          value: 55.0,
          raw_string: "55",
        },
      ],
    },
    {
      original_label: "Range",
      standardized_name: "Age Range",
      unit: "years",
      category: "Demographics",
      is_sub_characteristic: true,
      sub_characteristic_of: "Age, years",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.NumericMeanRange,
          range_min: 27.0,
          range_max: 83.0,
          raw_string: "27-83",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.NumericMeanRange,
          range_min: 31.0,
          range_max: 79.0,
          raw_string: "31-79",
        },
        {
          group_name: "Total",
          data_type: DataType.NumericMeanRange,
          range_min: 27.0,
          range_max: 83.0,
          raw_string: "27-83",
        },
      ],
    },
    {
      original_label: "ECOG performance status at baseline",
      standardized_name: "ECOG Performance Status",
      category: "Baseline Characteristics",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "ECOG performance status at baseline",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "ECOG performance status at baseline",
        },
        {
          group_name: "Total",
          data_type: DataType.Header,
          raw_string: "ECOG performance status at baseline",
        },
      ],
    },
    {
      original_label: "0",
      standardized_name: "ECOG 0",
      category: "Baseline Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "ECOG performance status at baseline",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 260.0,
          percentage: 96.0,
          raw_string: "260 96",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 261.0,
          percentage: 98.0,
          raw_string: "261 98",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 521.0,
          percentage: 96.0,
          raw_string: "521 96",
        },
      ],
    },
    {
      original_label: "1",
      standardized_name: "ECOG 1",
      category: "Baseline Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "ECOG performance status at baseline",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 9.0,
          percentage: 3.0,
          raw_string: "9 3",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 5.0,
          percentage: 2.0,
          raw_string: "5 2",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 14.0,
          percentage: 3.0,
          raw_string: "14 3",
        },
      ],
    },
    {
      original_label: "2",
      standardized_name: "ECOG 2",
      category: "Baseline Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "ECOG performance status at baseline",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 2.0,
          percentage: 1.0,
          raw_string: "2 1",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 3.0,
          percentage: 1.0,
          raw_string: "3 1",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 5.0,
          percentage: 1.0,
          raw_string: "5 1",
        },
      ],
    },
    {
      original_label: "Race",
      standardized_name: "Race",
      category: "Demographics",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 266.0,
          percentage: 98.0,
          raw_string: "266 98",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 261.0,
          percentage: 97.0,
          raw_string: "261 97",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 527.0,
          percentage: 98.0,
          raw_string: "527 98",
        },
      ],
    },
    {
      original_label: "HER2 status",
      standardized_name: "HER2 Status",
      category: "Disease Characteristics",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "HER2 status",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "HER2 status",
        },
        {
          group_name: "Total",
          data_type: DataType.Header,
          raw_string: "HER2 status",
        },
      ],
    },
    {
      original_label: "IHC 3+ and/or FISH positive",
      standardized_name: "IHC 3+ and/or FISH Positive",
      category: "Disease Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "HER2 status",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 233.0,
          percentage: 86.0,
          raw_string: "233 86",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 228.0,
          percentage: 85.0,
          raw_string: "228 85",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 461.0,
          percentage: 85.0,
          raw_string: "461 85",
        },
      ],
    },
    {
      original_label: "CISH positive",
      standardized_name: "CISH Positive",
      category: "Disease Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "HER2 status",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 29.0,
          percentage: 11.0,
          raw_string: "29 11",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 40.0,
          percentage: 15.0,
          raw_string: "40 15",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 69.0,
          percentage: 13.0,
          raw_string: "69 13",
        },
      ],
    },
    {
      original_label: "SISH positive",
      standardized_name: "SISH Positive",
      category: "Disease Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "HER2 status",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 2.0,
          raw_string: "2 < 1",
          notes: "Percentage is less than 1",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 0.0,
          percentage: 0.0,
          raw_string: "0 0",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 2.0,
          raw_string: "2 < 1",
          notes: "Percentage is less than 1",
        },
      ],
    },
    {
      original_label: "Not HER2 positive",
      standardized_name: "Not HER2 Positive",
      category: "Disease Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "HER2 status",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 3.0,
          percentage: 1.0,
          raw_string: "3 1",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 4.0,
          percentage: 1.0,
          raw_string: "4 1",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 7.0,
          percentage: 1.0,
          raw_string: "7 1",
        },
      ],
    },
    {
      original_label: "Estrogen receptor status",
      standardized_name: "Estrogen Receptor Status",
      category: "Disease Characteristics",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "Estrogen receptor status",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "Estrogen receptor status",
        },
        {
          group_name: "Total",
          data_type: DataType.Header,
          raw_string: "Estrogen receptor status",
        },
      ],
    },
    {
      original_label: "Positive",
      standardized_name: "Positive",
      category: "Disease Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "Estrogen receptor status",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 133.0,
          percentage: 49.0,
          raw_string: "133 49",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 122.0,
          percentage: 45.0,
          raw_string: "122 45",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 255.0,
          percentage: 47.0,
          raw_string: "255 47",
        },
      ],
    },
    {
      original_label: "Negative",
      standardized_name: "Negative",
      category: "Disease Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "Estrogen receptor status",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 135.0,
          percentage: 50.0,
          raw_string: "135 50",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 144.0,
          percentage: 54.0,
          raw_string: "144 54",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 279.0,
          percentage: 52.0,
          raw_string: "279 52",
        },
      ],
    },
    {
      original_label: "Unknown",
      standardized_name: "Unknown",
      category: "Disease Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "Estrogen receptor status",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 3.0,
          percentage: 1.0,
          raw_string: "3 1",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 3.0,
          percentage: 1.0,
          raw_string: "3 1",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 6.0,
          percentage: 1.0,
          raw_string: "6 1",
        },
      ],
    },
    {
      original_label: "Progesterone receptor status",
      standardized_name: "Progesterone Receptor Status",
      category: "Disease Characteristics",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "Progesterone receptor status",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "Progesterone receptor status",
        },
        {
          group_name: "Total",
          data_type: DataType.Header,
          raw_string: "Progesterone receptor status",
        },
      ],
    },
    {
      original_label: "Positive",
      standardized_name: "Positive",
      category: "Disease Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "Progesterone receptor status",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 98.0,
          percentage: 36.0,
          raw_string: "98 36",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 80.0,
          percentage: 30.0,
          raw_string: "80 30",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 178.0,
          percentage: 33.0,
          raw_string: "178 33",
        },
      ],
    },
    {
      original_label: "Negative",
      standardized_name: "Negative",
      category: "Disease Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "Progesterone receptor status",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 158.0,
          percentage: 58.0,
          raw_string: "158 58",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 173.0,
          percentage: 64.0,
          raw_string: "173 64",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 331.0,
          percentage: 61.0,
          raw_string: "331 61",
        },
      ],
    },
    {
      original_label: "Unknown",
      standardized_name: "Unknown",
      category: "Disease Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "Progesterone receptor status",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 15.0,
          percentage: 6.0,
          raw_string: "15 6",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 16.0,
          percentage: 6.0,
          raw_string: "16 6",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 31.0,
          percentage: 6.0,
          raw_string: "31 6",
        },
      ],
    },
    {
      original_label: "No. of involved sites",
      standardized_name: "Number of Involved Sites",
      category: "Disease Characteristics",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "No. of involved sites",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "No. of involved sites",
        },
        {
          group_name: "Total",
          data_type: DataType.Header,
          raw_string: "No. of involved sites",
        },
      ],
    },
    {
      original_label: "<= 2",
      standardized_name: "<= 2",
      category: "Disease Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "No. of involved sites",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 77.0,
          percentage: 28.0,
          raw_string: "77 28",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 78.0,
          percentage: 29.0,
          raw_string: "78 29",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 155.0,
          percentage: 29.0,
          raw_string: "155 29",
        },
      ],
    },
    {
      original_label: ">= 3",
      standardized_name: ">= 3",
      category: "Disease Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "No. of involved sites",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 194.0,
          percentage: 72.0,
          raw_string: "194 72",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 191.0,
          percentage: 71.0,
          raw_string: "191 71",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 385.0,
          percentage: 71.0,
          raw_string: "385 71",
        },
      ],
    },
    {
      original_label: "Stage IV at initial diagnosis",
      standardized_name: "Stage IV at Initial Diagnosis",
      category: "Disease Characteristics",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 104.0,
          percentage: 38.0,
          raw_string: "104 38",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 98.0,
          percentage: 36.0,
          raw_string: "98 36",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 202.0,
          percentage: 37.0,
          raw_string: "202 37",
        },
      ],
    },
    {
      original_label: "Prior treatment",
      standardized_name: "Prior Treatment",
      category: "Treatment History",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "Prior treatment",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "Prior treatment",
        },
        {
          group_name: "Total",
          data_type: DataType.Header,
          raw_string: "Prior treatment",
        },
      ],
    },
    {
      original_label: "Trastuzumab naive prior met treatment",
      standardized_name: "Trastuzumab Naive Prior Metastatic Treatment",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of: "Prior treatment",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 59.0,
          percentage: 22.0,
          raw_string: "59 22",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 58.0,
          percentage: 22.0,
          raw_string: "58 22",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 117.0,
          percentage: 22.0,
          raw_string: "117 22",
        },
      ],
    },
    {
      original_label: "Prior trastuzumab/<= 1 prior met treatment",
      standardized_name:
        "Prior Trastuzumab and <= 1 Prior Metastatic Treatment",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of: "Prior treatment",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 108.0,
          percentage: 40.0,
          raw_string: "108 40",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 101.0,
          percentage: 38.0,
          raw_string: "101 38",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 209.0,
          percentage: 39.0,
          raw_string: "209 39",
        },
      ],
    },
    {
      original_label: "Prior trastuzumab/>= 2 prior met treatment",
      standardized_name:
        "Prior Trastuzumab and >= 2 Prior Metastatic Treatments",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of: "Prior treatment",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 58.0,
          percentage: 21.0,
          raw_string: "58 21",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 63.0,
          percentage: 23.0,
          raw_string: "63 23",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 121.0,
          percentage: 22.0,
          raw_string: "121 22",
        },
      ],
    },
    {
      original_label: "No prior trastuzumab/>= 1 prior met treatment",
      standardized_name:
        "No Prior Trastuzumab and >= 1 Prior Metastatic Treatment",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of: "Prior treatment",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 46.0,
          percentage: 17.0,
          raw_string: "46 17",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 47.0,
          percentage: 17.0,
          raw_string: "47 17",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 93.0,
          percentage: 17.0,
          raw_string: "93 17",
        },
      ],
    },
    {
      original_label: "Patients who received prior chemotherapy",
      standardized_name: "Prior Chemotherapy Use",
      category: "Treatment History",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 249.0,
          percentage: 92.0,
          raw_string: "249 92",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 245.0,
          percentage: 91.0,
          raw_string: "245 91",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 494.0,
          percentage: 91.0,
          raw_string: "494 91",
        },
      ],
    },
    {
      original_label: "Adjuvant",
      standardized_name: "Adjuvant Setting",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of: "Patients who received prior chemotherapy",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 158.0,
          percentage: 58.0,
          raw_string: "158 58",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 173.0,
          percentage: 64.0,
          raw_string: "173 64",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 331.0,
          percentage: 61.0,
          raw_string: "331 61",
        },
      ],
    },
    {
      original_label: "Metastatic",
      standardized_name: "Metastatic Setting",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of: "Patients who received prior chemotherapy",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 91.0,
          percentage: 34.0,
          raw_string: "91 34",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 72.0,
          percentage: 27.0,
          raw_string: "72 27",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 163.0,
          percentage: 30.0,
          raw_string: "163 30",
        },
      ],
    },
    {
      original_label: "No. of prior treatments for metastatic disease",
      standardized_name: "No Prior Treatments for Metastatic Disease",
      category: "Treatment History",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 117.0,
          percentage: 43.0,
          raw_string: "117 43",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 121.0,
          percentage: 45.0,
          raw_string: "121 45",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 238.0,
          percentage: 44.0,
          raw_string: "238 44",
        },
      ],
    },
    {
      original_label: "Patients who received prior trastuzumab",
      standardized_name: "Prior Trastuzumab Use",
      category: "Treatment History",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 154.0,
          percentage: 57.0,
          raw_string: "154 57",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 148.0,
          percentage: 55.0,
          raw_string: "148 55",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 302.0,
          percentage: 56.0,
          raw_string: "302 56",
        },
      ],
    },
    {
      original_label: "Adjuvant",
      standardized_name: "Adjuvant Setting",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of: "Patients who received prior trastuzumab",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 73.0,
          percentage: 27.0,
          raw_string: "73 27",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 78.0,
          percentage: 29.0,
          raw_string: "78 29",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 151.0,
          percentage: 28.0,
          raw_string: "151 28",
        },
      ],
    },
    {
      original_label: "Metastatic",
      standardized_name: "Metastatic Setting",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of: "Patients who received prior trastuzumab",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 81.0,
          percentage: 30.0,
          raw_string: "81 30",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 70.0,
          percentage: 26.0,
          raw_string: "70 26",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 151.0,
          percentage: 28.0,
          raw_string: "151 28",
        },
      ],
    },
    {
      original_label: "Duration of prior trastuzumab treatment, months",
      standardized_name: "Duration of Prior Trastuzumab Treatment",
      unit: "months",
      category: "Treatment History",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "Duration of prior trastuzumab treatment, months",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "Duration of prior trastuzumab treatment, months",
        },
        {
          group_name: "Total",
          data_type: DataType.Header,
          raw_string: "Duration of prior trastuzumab treatment, months",
        },
      ],
    },
    {
      original_label: "Median",
      standardized_name: "Duration of Prior Trastuzumab Treatment",
      unit: "months",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of: "Duration of prior trastuzumab treatment, months",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.NumericSingle,
          value: 11.9,
          raw_string: "11.9",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.NumericSingle,
          value: 11.8,
          raw_string: "11.8",
        },
        {
          group_name: "Total",
          data_type: DataType.NumericSingle,
          value: 11.8,
          raw_string: "11.8",
        },
      ],
    },
    {
      original_label: "Range",
      standardized_name: "Duration of Prior Trastuzumab Treatment Range",
      unit: "months",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of: "Duration of prior trastuzumab treatment, months",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.NumericMeanRange,
          range_min: 1.0,
          range_max: 69.5,
          raw_string: "1.0-69.5",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.NumericMeanRange,
          range_min: 0.0,
          range_max: 96.1,
          raw_string: "0.0-96.1",
        },
        {
          group_name: "Total",
          data_type: DataType.NumericMeanRange,
          range_min: 0.0,
          range_max: 96.1,
          raw_string: "0.0-96.1",
        },
      ],
    },
    {
      original_label:
        "Duration of prior metastatic trastuzumab treatment, months",
      standardized_name: "Duration of Prior Metastatic Trastuzumab Treatment",
      unit: "months",
      category: "Treatment History",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.Header,
          raw_string:
            "Duration of prior metastatic trastuzumab treatment, months",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.Header,
          raw_string:
            "Duration of prior metastatic trastuzumab treatment, months",
        },
        {
          group_name: "Total",
          data_type: DataType.Header,
          raw_string:
            "Duration of prior metastatic trastuzumab treatment, months",
        },
      ],
    },
    {
      original_label: "Median",
      standardized_name: "Duration of Prior Metastatic Trastuzumab Treatment",
      unit: "months",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of:
        "Duration of prior metastatic trastuzumab treatment, months",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.NumericSingle,
          value: 11.8,
          raw_string: "11.8",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.NumericSingle,
          value: 13.4,
          raw_string: "13.4",
        },
        {
          group_name: "Total",
          data_type: DataType.NumericSingle,
          value: 12.1,
          raw_string: "12.1",
        },
      ],
    },
    {
      original_label: "Range",
      standardized_name:
        "Duration of Prior Metastatic Trastuzumab Treatment Range",
      unit: "months",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of:
        "Duration of prior metastatic trastuzumab treatment, months",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.NumericMeanRange,
          range_min: 1.0,
          range_max: 69.5,
          raw_string: "1.0-69.5",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.NumericMeanRange,
          range_min: 0.0,
          range_max: 96.1,
          raw_string: "0.0-96.1",
        },
        {
          group_name: "Total",
          data_type: DataType.NumericMeanRange,
          range_min: 0.0,
          range_max: 96.1,
          raw_string: "0.0-96.1",
        },
      ],
    },
    {
      original_label:
        "Duration of most recent prior metastatic trastuzumab treatment, months",
      standardized_name:
        "Duration of Most Recent Prior Metastatic Trastuzumab Treatment",
      unit: "months",
      category: "Treatment History",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.Header,
          raw_string:
            "Duration of most recent prior metastatic trastuzumab treatment, months",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.Header,
          raw_string:
            "Duration of most recent prior metastatic trastuzumab treatment, months",
        },
        {
          group_name: "Total",
          data_type: DataType.Header,
          raw_string:
            "Duration of most recent prior metastatic trastuzumab treatment, months",
        },
      ],
    },
    {
      original_label: "Median",
      standardized_name:
        "Duration of Most Recent Prior Metastatic Trastuzumab Treatment",
      unit: "months",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of:
        "Duration of most recent prior metastatic trastuzumab treatment, months",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.NumericSingle,
          value: 10.4,
          raw_string: "10.4",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.NumericSingle,
          value: 10.9,
          raw_string: "10.9",
        },
        {
          group_name: "Total",
          data_type: DataType.NumericSingle,
          value: 10.6,
          raw_string: "10.6",
        },
      ],
    },
    {
      original_label: "Range",
      standardized_name:
        "Duration of Most Recent Prior Metastatic Trastuzumab Treatment Range",
      unit: "months",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of:
        "Duration of most recent prior metastatic trastuzumab treatment, months",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.NumericMeanRange,
          range_min: 0.0,
          range_max: 69.5,
          raw_string: "0.0-69.5",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.NumericMeanRange,
          range_min: 0.0,
          range_max: 96.1,
          raw_string: "0.0-96.1",
        },
        {
          group_name: "Total",
          data_type: DataType.NumericMeanRange,
          range_min: 0.0,
          range_max: 96.1,
          raw_string: "0.0-96.1",
        },
      ],
    },
    {
      original_label:
        "Patients who also received prior anthracycline and taxane",
      standardized_name: "Prior Anthracycline and Taxane Use",
      category: "Treatment History",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 238.0,
          percentage: 88.0,
          raw_string: "238 88",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 234.0,
          percentage: 87.0,
          raw_string: "234 87",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 472.0,
          percentage: 87.0,
          raw_string: "472 87",
        },
      ],
    },
    {
      original_label: "Anthracycline",
      standardized_name: "Prior Anthracycline Use",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of:
        "Patients who also received prior anthracycline and taxane",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 258.0,
          percentage: 95.0,
          raw_string: "258 95",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 253.0,
          percentage: 94.0,
          raw_string: "253 94",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 511.0,
          percentage: 95.0,
          raw_string: "511 95",
        },
      ],
    },
    {
      original_label: "Metastatic",
      standardized_name: "Metastatic Setting",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of: "Anthracycline",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 56.0,
          percentage: 21.0,
          raw_string: "56 21",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 55.0,
          percentage: 20.0,
          raw_string: "55 20",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 111.0,
          percentage: 21.0,
          raw_string: "111 21",
        },
      ],
    },
    {
      original_label: "Taxane",
      standardized_name: "Prior Taxane Use",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of:
        "Patients who also received prior anthracycline and taxane",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 249.0,
          percentage: 92.0,
          raw_string: "249 92",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 249.0,
          percentage: 93.0,
          raw_string: "249 93",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 498.0,
          percentage: 92.0,
          raw_string: "498 92",
        },
      ],
    },
    {
      original_label: "Adjuvant",
      standardized_name: "Adjuvant Setting",
      category: "Treatment History",
      is_sub_characteristic: true,
      sub_characteristic_of: "Taxane",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 47.0,
          percentage: 17.0,
          raw_string: "47 17",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.CategoricalCountPercentage,
          count: 61.0,
          percentage: 23.0,
          raw_string: "61 23",
        },
        {
          group_name: "Total",
          data_type: DataType.CategoricalCountPercentage,
          count: 108.0,
          percentage: 20.0,
          raw_string: "108 20",
        },
      ],
    },
    {
      original_label: "Time since initial diagnosis, years",
      standardized_name: "Time Since Initial Diagnosis",
      unit: "years",
      category: "Disease Characteristics",
      is_sub_characteristic: false,
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "Time since initial diagnosis, years",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.Header,
          raw_string: "Time since initial diagnosis, years",
        },
        {
          group_name: "Total",
          data_type: DataType.Header,
          raw_string: "Time since initial diagnosis, years",
        },
      ],
    },
    {
      original_label: "Median",
      standardized_name: "Time Since Initial Diagnosis",
      unit: "years",
      category: "Disease Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "Time since initial diagnosis, years",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.NumericSingle,
          value: 2.6,
          raw_string: "2.6",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.NumericSingle,
          value: 3.0,
          raw_string: "3.0",
        },
        {
          group_name: "Total",
          data_type: DataType.NumericSingle,
          value: 2.8,
          raw_string: "2.8",
        },
      ],
    },
    {
      original_label: "Range",
      standardized_name: "Time Since Initial Diagnosis Range",
      unit: "years",
      category: "Disease Characteristics",
      is_sub_characteristic: true,
      sub_characteristic_of: "Time since initial diagnosis, years",
      group_data: [
        {
          group_name: "Lapatinib plus Capecitabine",
          data_type: DataType.NumericMeanRange,
          range_min: 0.0,
          range_max: 18.0,
          raw_string: "0-18",
        },
        {
          group_name: "Trastuzumab plus Capecitabine",
          data_type: DataType.NumericMeanRange,
          range_min: 0.0,
          range_max: 25.0,
          raw_string: "0-25",
        },
        {
          group_name: "Total",
          data_type: DataType.NumericMeanRange,
          range_min: 0.0,
          range_max: 25.0,
          raw_string: "0-25",
        },
      ],
    },
  ],
};
